Le Lézard
Classified in: Ebola virus, Health, Business
Subject: TNM

Pre-conditional public offer announced for 100% of the shares in Essity's subsidiary Vinda


STOCKHOLM, Dec. 15, 2023 /PRNewswire/ -- Isola Castle Ltd, a company indirectly wholly owned by Asia Pacific Resources International Limited (APRIL), has today announced that it will make a pre-conditional public offer to the shareholders of Vinda International Holdings Limited (Vinda) to acquire 100% of the shares in Vinda for a price per share of HKD 23.50. Essity supports the offer and has signed an irrevocable undertaking to accept the offer in respect of all of its 51.59% shareholding in Vinda. The price in the public offer will correspond to an equity value of Vinda of approximately HKD 28.3bn (SEK 37.3bn).

The transaction is expected to generate cash proceeds to Essity of approximately HKD 15bn (SEK 19bn). 

An exclusive license to continue to market and sell certain Essity branded products will be offered to Vinda after closing of the transaction to replace the existing license agreement. 

"This is a very attractive offer for Essity and for our shareholders. We maintain a presence in Asia and in Vinda through continued licensing of Essity's brands, with sustainability requirements for sourcing, production and collaboration in innovation and marketing. After completion of the bid, we will also reduce Consumer Tissue's share of Essity's total sales and enable increased focus on investments and growth in Essity's brands and higher yielding categories," says Magnus Groth, President and CEO of Essity.

Essity's ownership of 51.59% in Vinda has been consolidated 100% by Essity since 2014. Vinda is listed on the Hong Kong Stock Exchange and had a market capitalization of approximately HKD 25bn (SEK 33bn) at the end of trading on December 14, 2023. Vinda's net sales in 2022 amounted to approximately SEK 25.1bn and EBITA amounted to approximately SEK 1.1bn. Of Vinda's net sales, 83% were related to tissue and 17% were related to personal care. 

As of Q4 2023, Essity will classify the financial reporting of Vinda as discontinued operations. Essity will shortly provide updated comparable figures. Essity's financial targets for annual sales growth and adjusted ROCE will be reviewed as a consequence of this transaction. After legal consultation Essity has concluded that a divestment of its shares in Vinda, where Essity remains with its business through brands, technologies and innovations, and licensed sales, does not constitute cessation of business under Essity's EMTN program.

The launch of the offer and completion of the transaction are subject to approval by regulatory authorities in China and other relevant markets. The transaction is expected to be completed mid-2024.

Conference call for investors, analysts and media
A conference call will be held today, December 15, at 09:00 CET with Essity's President and CEO Magnus Groth. The conference call will be live webcasted at https://essity.videosync.fi/2023-12-15 

You can also participate and ask questions by telephone, call: UK: +44 (0) 33 0551 02 00, USA: +1 786 697 35 01, SWE: +46 (0) 8 505 204 24 and indicate "Essity"

NB: This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 00:35 CET on December 15, 2023.

Karl Stoltz, Media Relations Director, +46 709 426 338

CONTACT:

For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 73 313 30 55, [email protected]
Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89, [email protected]

The following files are available for download:

https://mb.cision.com/Main/15798/3894167/2496616.pdf

Pre-conditional public offer announced for 100% of the shares in Essityâ?tms subsidiary Vinda


These press releases may also interest you

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
Women's Heart Health Month is recognized every May and is focused on raising awareness about cardiovascular health among women. It aims to educate women about the risks, symptoms, and prevention of heart disease, which is the leading cause of death...

4 mai 2024
RaySearch Laboratories AB (publ) and C-RAD are pleased to announce a collaboration agreement, aiming at jointly developing innovative solutions and products to enhance the quality of radiation therapy. The focus of the collaboration is to...

4 mai 2024
SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility...



News published on and distributed by: